CollPlant Biotechnologies’ (CLGN) “Buy” Rating Reaffirmed at D. Boral Capital

CollPlant Biotechnologies (NASDAQ:CLGN)‘s stock had its “buy” rating reiterated by investment analysts at D. Boral Capital in a report issued on Wednesday,Benzinga reports. They currently have a $14.00 price target on the stock. D. Boral Capital’s target price would suggest a potential upside of 229.53% from the company’s previous close.

Several other research firms also recently issued reports on CLGN. EF Hutton Acquisition Co. I upgraded CollPlant Biotechnologies to a “strong-buy” rating in a research report on Monday, August 5th. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of CollPlant Biotechnologies in a research note on Wednesday, August 21st.

CollPlant Biotechnologies Stock Down 0.4 %

NASDAQ CLGN opened at $4.25 on Wednesday. The firm has a market cap of $48.67 million, a P/E ratio of -2.76 and a beta of 0.44. The company’s 50 day moving average is $4.30 and its 200-day moving average is $4.85. CollPlant Biotechnologies has a 12-month low of $3.31 and a 12-month high of $6.99.

Institutional Trading of CollPlant Biotechnologies

A number of hedge funds and other institutional investors have recently bought and sold shares of CLGN. Villere ST Denis J & Co. LLC grew its position in shares of CollPlant Biotechnologies by 24.4% during the 3rd quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock valued at $2,407,000 after purchasing an additional 95,000 shares in the last quarter. Pinnacle Associates Ltd. boosted its stake in CollPlant Biotechnologies by 6.4% during the second quarter. Pinnacle Associates Ltd. now owns 564,360 shares of the company’s stock valued at $2,805,000 after buying an additional 33,905 shares during the period. Finally, Benjamin Edwards Inc. purchased a new position in CollPlant Biotechnologies during the third quarter worth about $112,000. Institutional investors own 21.69% of the company’s stock.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.